Why is Exelixis, Inc. ?
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 13.05%
- Healthy long term growth as Net Sales has grown by an annual rate of 18.63%
- The company is Net-Debt Free
2
With a growth in Net Profit of 31.86%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 3 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 924.67 MM
- NET PROFIT(HY) At USD 455.67 MM has Grown at 52.06%
- ROCE(HY) Highest at 40.99%
3
With ROE of 36.94%, it has a attractive valuation with a 4.99 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 20.24%, its profits have risen by 36.2% ; the PEG ratio of the company is 0.3
4
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
How much should you buy?
- Overall Portfolio exposure to Exelixis, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Exelixis, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Exelixis, Inc.
20.24%
3.37
39.69%
S&P 500
22.99%
1.78
12.93%
Quality key factors
Factor
Value
Sales Growth (5y)
18.63%
EBIT Growth (5y)
51.99%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.48
Sales to Capital Employed (avg)
0.95
Tax Ratio
23.21%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
32.49%
ROE (avg)
13.05%
Valuation Key Factors 
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
4.99
EV to EBIT
10.93
EV to EBITDA
10.58
EV to Capital Employed
8.63
EV to Sales
4.20
PEG Ratio
0.30
Dividend Yield
NA
ROCE (Latest)
78.99%
ROE (Latest)
36.94%
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
Technical Movement
13What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 924.67 MM
NET PROFIT(HY)
At USD 455.67 MM has Grown at 52.06%
ROCE(HY)
Highest at 40.99%
NET SALES(Q)
Highest at USD 610.81 MM
RAW MATERIAL COST(Y)
Fallen by -0.19% (YoY
-2What is not working for the Company
CASH AND EQV(HY)
Lowest at USD 1,836.3 MM
DEBT-EQUITY RATIO
(HY)
Highest at -31.39 %
Here's what is working for Exelixis, Inc.
Operating Cash Flow
Highest at USD 924.67 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 610.81 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Profit
At USD 455.67 MM has Grown at 52.06%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Raw Material Cost
Fallen by -0.19% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Exelixis, Inc.
Cash and Eqv
Lowest at USD 1,836.3 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at -31.39 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio






